Pioneering diagnostics
E.g., 18/04/2014
E.g., 18/04/2014

Alexandre Mérieux Assumes Role of bioMérieux CEO

15 April, 2014

Marcy l’Etoile (France), April 15, 2014 - Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic plan, a new organization is being deployed.

The...

bioMérieux - 2013 Financial Results

19 March, 2014

HIGHLIGHTS

Objectives met

  • Solid financial performance
  • Sales up 4.6% at constant exchange rates and scope of consolidation
  • Operating income before non-recurring items: €262 million, or 16....

bioMérieux strengthens its Clostridium difficile offer with the launch of VIDAS® C. difficile GDH

VIDAS® C. difficile GDH is the 100th assay for use on VIDAS® range VIDAS® C. difficile GDH is the only FDA-approved automated immunoassay parameter for GDH* detection * Glutamate dehydrogenase

26 February, 2014

Marcy l'Étoile, France, February 26, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that the launch of VIDAS®C. difficile GDH makes it the only company with the width to provide...

BioFire Submits 510(k) Application to FDA for FilmArray® Gastrointestinal Panel

19 February, 2014

BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The comprehensive FilmArray GI Panel tests for over 20 common bacteria, viruses and parasites that cause infectious...

Appointment of Claire Giraut as bioMérieux’s Corporate Vice President & Chief Financial Officer

27 January, 2014

Marcy l’Etoile, France, January 27, 2014 bioMérieux, a world leader in the field of in vitro diagnostics, announces that Claire Giraut has been appointed Corporate Vice President & Chief Financial Officer.

Claire Giraut...

Business Review for the year ended December 31, 2013

22 January, 2014

  • 2013: solid 4.6% organic growth in sales
    • At the top end of the target range announced early in the year
    • Faster organic growth in North America and firmer business in Western Europe
    • Sustained fast growth in...

bioMérieux finalizes acquisition of the U.S. company BioFire, specialized in molecular biology

With this acquisition, bioMérieux consolidates its position as a major player in infectious disease diagnostics and strengthens its presence in the United States

16 January, 2014

Marcy l'Etoile, France, January 16, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized its acquisition of 100% ownership in BioFire Diagnostics Inc., a privately held U.S.-based company specialized in...

bioMérieux is Moving Forward to a New Molecular Biology Workflow Solution for Reference or Centralized Laboratories

05 December, 2013

Marcy l'Étoile, France, December 5th, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, has announced that it is moving a new step forward to its comprehensive automation solution dedicated for reference or centralized molecular...

bioMérieux Announces Termination of its Collaboration with Biocartis in Molecular Biology

28 November, 2013

Marcy l'Etoile, France, le 28 novembre 2013 - D’un commun accord, bioMérieux, acteur mondial du diagnostic in vitro, et Biocartis ont décidé de mettre fin à leur collaboration pour le développement et la commercialisation d’un système intégré...

bioMérieux launches the Parvovirus B19 R-gene® kit, a new ARGENE® test for the detection and quantification of the three Parvovirus B19 genotypes

29 October, 2013

Marcy l'Étoile, France, October 28, 2013 - bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of the Parvovirus B19 R-gene® kit, a new CE-marked ARGENE® real-time PCR test, used for the detection...